Product Info
NOWONDER™ (previously Enovid), is designed to clean the upper airway of viruses, preventing them from incubating and spreading to the lungs. Each bottle of Enovid/NOWONDER™ contains a 1 month supply.
US$59.00
| Quantity | Unit Price |
| 1 | US$59.00 |
| 2 | US$48.00 |
| 3 | US$45.00 |
| 4 - 7 | US$40.00 |
| 8 + | US$37.00 |
NOWONDER™ (previously Enovid), is designed to clean the upper airway of viruses, preventing them from incubating and spreading to the lungs. Each bottle of Enovid/NOWONDER™ contains a 1 month supply.
Enovid/NOWONDER™ is a Nitric Oxide Release Spray (NORS), which protects users from viruses that enter the body through the upper nasal pathways. Each bottle contains enough supply for 1 month.
Click here for the Enovid User Guide.
Enovid/NOWONDER™ is designed to kill viruses, such as the SARs-CoV-2 that causes COVID-19, in the upper airways, preventing them from incubating and spreading to the lungs.
Enovid/NOWONDER™ is like a “hand sanitizer equivalent for the nose,” and creates a physical barrier in the nasal passages to stop viruses along with a “chemical barrier” of nitric oxide, which is known for its antimicrobial qualities.
Enovid/NOWONDER™ shields against viruses and should be administered before and after suspected exposure to viruses by individuals in high-risk environments (i.e. public transportation, health care settings, daycares, shopping centers, sports events, etc)
Enovid/NOWONDER™ may be applied 2-3 times over the day or up to 5 times a day following suspected virus exposure.
Good for 6 months once opened.
Ingredients
Sodium chloride, citric acid, HPMC, sodium nitrite, Benzalkonium Chloride
Why isn’t Nitric Oxide listed as one of the ingredients? A small amount of Nitric oxide is being created once the spray is being used. This is a patented technology that is creating nitric oxide.
In a randomized, double-blind, placebo-controlled Phase 2 trial that evaluated 79 confirmed cases of COVID-19, SaNOtize’s early treatment for COVID-19 significantly reduced the level of SARS-CoV-2, including in patients with high viral loads. The average viral log reduction in the first 24 hours was 1.362, which corresponds to a decline of about 95%. Within 72 hours, the viral load dropped by more than 99%. The majority of these patients had been infected with the UK variant, which is considered a variant of concern.
Data was published at the Journal of Infection
* These statements have not been evaluated by the Food and Drug Administration.
These products are not intended to diagnose, treat, cure, or prevent any disease.
